Missed Signals, System Failures, and the Expanding Scope of Liability: Lessons from a $49 Million Connecticut Cervical Cancer Verdict

A recent $49 million jury award out of Connecticut against Westchester Medical Group PC reflects a noticeable shift in how medical malpractice claims are being framed and decided. Rather than focusing on a single misstep by a provider, the case—brought by Jennifer Anderson and her husband—centered on a pattern of missed opportunities within a preventive screening process. Anderson allegedly presented for years with repeated high-risk HPV findings, yet the follow-up care that should have been triggered never materialized, ultimately allowing her cervical cancer to advance to a metastatic stage. For practitioners in this space, the takeaway is hard to ignore: juries are showing a growing willingness to hold providers accountable not just for individual decisions, but for breakdowns in the systems meant to catch these conditions early.

I. Clinical Context and the Legal Architecture of Screening Obligations

Cervical cancer is among the most preventable malignancies in modern medicine, primarily due to the integration of cytology (Pap testing), HPV screening, and diagnostic escalation tools such as colposcopy. Persistent infection with high-risk HPV strains, particularly HPV-16, is recognized as the primary etiologic factor in cervical carcinogenesis. Consequently, screening paradigms are structured to identify precancerous changes before malignant progression occurs.

As medical literature regularly demonstrates, HPV testing functions as a triage mechanism, identifying patients at elevated risk who call for further diagnostic evaluation, often through colposcopy and biopsy. See, e.g., Saslow et al., American Cancer Society Guideline for the Early Detection of Cervical Cancer, 62 CA Cancer J. Clin. 147, 147–72 (2012) (establishing co-testing protocols and escalation pathways); Moyer, Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement, 156 Ann. Intern. Med. 880 (2012). Those frameworks are not aspirational—they are the backbone of the applicable standard of care.

Indeed, clinical literature reflects that colposcopy is a routine and expected diagnostic step when screening reveals abnormalities or persistent high-risk HPV. Cervical Cancer Treatment (PDQ®), PeaceHealth, https://www.peacehealth.org/medical-topics/id/ncicdr0000062759 (last visited Apr. 26, 2026).

The legal implication is clear: once a patient enters a defined screening pathway, providers have a duty to order, interpret, track, and act upon test results within accepted clinical timelines.

The Anderson case illustrates a broader litigation trend that redirects focus from isolated negligent acts to failures across the continuum of care. Plaintiffs alleged that over several years, Anderson exhibited repeated indicators of high-risk HPV but was not referred for colposcopic evaluation. This failure, they argued, breached the standard of care because persistent HPV infection is a clinically significant finding that requires intervention.

Medical scholarship supports the plaintiffs’ framing. Persistent HPV infection significantly increases the risk of progression to high-grade cervical lesions and invasive cancer if not properly monitored and treated. See Goldie et al., Cost-Effectiveness of Cervical Cancer Screening, 100 J. Nat’l Cancer Inst. 308 (2008). Moreover, delays in diagnostic follow-up have been directly associated with worsened outcomes. See Benard et al., Timeliness of Cervical Cancer Diagnosis, 21 J. Women’s Health 776 (2012).

The plaintiffs’ causation argument, often the most contested element in delayed diagnosis cases, was based on the premise that earlier intervention would have materially altered Anderson’s prognosis. Courts have increasingly accepted this theory when the disease process is well-characterized and the window for intervention is clinically established.

Westmed’s defense, as reported, centered on disputing liability and preserving post-trial challenges. While details of expert testimony are limited, such defenses generally rely on arguments that (1) screening results did not mandate escalation under the circumstances, or (2) the progression of disease was not preventable even with earlier intervention.

However, these arguments encounter increasing challenges in cases involving structured screening procedures. While the defense may contend that clinical discretion is warranted in interpreting screening results or determining escalation, preventive care pathways are inherently algorithmic. When guidelines specify explicit next steps, such as colposcopy following persistent high-risk HPV, courts are less receptive to claims of individualized judgment, and deviation is more readily characterized as negligence rather than a reasonable clinical decision.

Additionally, juries are less persuaded by defenses that isolate individual clinical encounters. The prevailing trend is to view care longitudinally. When a patient consistently presents, complies with testing, and stays within a healthcare system, responsibility for continuity of care rests with providers.

This case is distinguished by the plaintiffs’ concentration on operational failures. Specifically, the allegations included improper handling of laboratory orders, inadequate transition from paper to electronic medical records, and insufficient staff training.

These claims move past traditional malpractice into the domain of institutional liability. Courts have long recognized that hospitals and medical groups may be liable for structural deficiencies that undermine patient care. See Darling v. Charleston Cmty. Mem’l Hosp., 211 N.E.2d 253 (Ill. 1965). The Anderson case constitutes a modern application of that principle in the outpatient, group-practice setting.

The adoption of electronic medical records (EMRs) has created distinct liability risks. Issues such as flawed data migration, incomplete records, and insufficient staff training can disrupt care continuity, especially in preventive screening programs reliant on sustained monitoring. When these shortcomings result in missed follow-up, they are viewed as actionable breaches of duty rather than simple administrative errors.

The $49 million verdict, which includes substantial non-economic damages and a significant loss-of-consortium award, reflects the emotional importance juries assign to preventable harm. Cervical cancer, more than many other malignancies, is associated with a depiction of avoidability. As one recent report observed, the disease is “highly preventable and treatable” when detected early. See Alex Putterman, For Patients Avoiding Pelvic Exams, At-Home HPV Tests Open the Door to Care, CT Experts Say, CT Insider (Feb. 5, 2026), https://www.ctinsider.com/connecticut/article/cervical-cancer-hpv-screening-tool-ct-21320487.php

This perception influences the assessment of damages. Jurors respond not only to the injury itself but also to a perceived failure of a system intended to prevent these outcomes. This often results in substantial non-economic awards, particularly when the plaintiff was compliant with care recommendations.

For medical malpractice practitioners—both plaintiff and defense—the Anderson verdict offers several concrete lessons.

First, screening cases are no longer considered low-exposure matters. Although historically viewed as routine negligence claims, they now carry substantial verdict potential when framed as systematic failures.

Second, documentation alone is insufficient. The presence of test results in a chart does not protect providers if there is no evidence of appropriate follow-up. Plaintiffs are increasingly concentrating on actions taken, or not taken, in response to known risks.

Third, EMR systems have served as a focal point in litigation. Practitioners should anticipate that discovery will examine not only clinical decisions but also system design, training protocols, and data quality.

Fourth, causation defenses have to adapt. In cases involving well-understood disease progression, generalized arguments regarding inevitability are unlikely to succeed. Defense counsel must engage with medical literature to identify plausible alternative pathways.

Finally, loss-of-chance theories are gaining acceptance. Even when a cure cannot be definitively established, the loss of an opportunity for earlier intervention may be sufficient to support liability and significant damages.

The Connecticut verdict against Westmed is not simply a high-value outlier; it represents a doctrinal shift. It shows a judicial and jury-level recognition that, in modern medicine, negligence frequently stems from a series of missed signals within systems designed to detect them.

The central takeaway for practitioners is that medical malpractice litigation involving preventive screening now prioritizes systemic and structural deficiencies over individual errors. Determinations of liability are increasingly predicated on whether providers consistently followed established clinical protocols, maintained continuity of patient care, and implemented operational systems capable of reliably translating clinical data into timely interventions.

In this context, successful advocacy on either side requires more than clinical expertise. It requires a thorough knowledge of how preventive care is delivered, documented, and operationalized. Those who can frame the case within this wider framework will be best positioned to influence the future direction of medical negligence jurisprudence.